The current COVID-19 outbreak warrants the design and development of novel anti-COVID
therapeutics. Using a combination of bioinformatics and computational tools, we modelled …

The SARS-CoV-2 main protease (Mpro) is a major therapeutic target. The Mpro inhibitor,
nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID …

Favipiravir is a novel broad-spectrum antiviral drug against RNA viruses that has been
approved for the treatment of seasonal and pandemic influenza. The use of favipiravir is a …

COVID-19 has emerged as a rapidly escalating serious global health issue, affecting every
section of population in a detrimental way. Present situation invigorated researchers to look …

Abstract The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) became a pandemic, resulting in an exponentially …

Background SARS-CoV-2 is a newly emerged human coronavirus that severely affected
human health and the economy. The viral RNA-dependent RNA polymerase (RdRp) is a …

Three anti-HIV drugs, ritonavir, lopinavir and darunavir, might have therapeutic effect on
coronavirus disease 2019 (COVID-19). In this study, the structure models of two severe …

The COVID-19 pandemic continues to be a public health threat with emerging variants of
SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the …

The devastating effect of SARS-CoV2 continues and the scientific community is pursuing to
find the strategy to combat the spread of the virus. The approach is adapted to target this …

Aims A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began
spreading in December 2019 in Wuhan City, China causing pneumonia called COVID-19 …